NEW YORK, NY – [Date of Article] – In a landmark development set to redefine personal mobility, Wandercraft, a pioneering French robotics company, has announced that its innovative self-balancing personal exoskeleton, Eve, has received clearance from the U.S. Food and Drug Administration (FDA). This pivotal authorization paves the way for eligible wheelchair users to experience hands-free upright mobility in their daily lives, moving beyond the confines of traditional rehabilitation settings and into the rhythm of ordinary moments that often hold extraordinary meaning.
The FDA clearance for Eve signifies a monumental leap in assistive technology, transforming the landscape for individuals with spinal cord injuries and other mobility impairments. For years, the ability to stand and walk upright has largely been confined to clinical environments, demanding extensive physical effort and constant supervision. Eve’s introduction promises to democratize this capability, offering a new dimension of independence and participation in society.
A New Era of Upright Mobility: Main Facts
Wandercraft’s Eve is engineered to support upright mobility for eligible adults with spinal cord injuries at any level. Its defining feature is its advanced self-balancing technology, which allows users to walk and perform activities of daily living hands-free, controlled via a remote device. This unprecedented level of autonomy distinguishes Eve from many existing exoskeletons, which often require crutches or significant upper body involvement for balance.
The device is specifically intended for use on level indoor surfaces and adjacent open-air areas that are part of a building, such as patios and terraces. Crucially, its operation is designed to be undertaken under the supervision of a specially trained companion, ensuring safety and optimal utilization in real-world environments.
Wandercraft emphasizes that Eve is designed to complement, rather than replace, the wheelchair. It offers users expanded opportunities to stand, walk, bend, turn, and utilize their hands freely, integrating upright participation into a broader spectrum of everyday activities. This dual approach ensures that individuals retain the flexibility and convenience of their wheelchairs while gaining the transformative benefits of standing and walking when desired.
"FDA clearance of Eve marks one of the most important moments in Wandercraft’s history and a significant step for the people, families, clinicians, researchers, and partners who helped make it possible," stated Matthieu Masselin, co-founder and CEO of Wandercraft. "Together, Atalante X and Eve may offer eligible users a pathway from walking during rehabilitation to upright mobility at home, whether making coffee at the kitchen counter, reaching for a book, or spending time with friends on the patio." Masselin’s comments underscore the company’s vision of a holistic care pathway, bridging the gap between clinical intervention and personal empowerment.
The Genesis of Innovation: A Chronology of Progress
Wandercraft’s journey to Eve is built upon a foundation of extensive experience and technological prowess, notably with its rehabilitation exoskeleton, Atalante X. This clinical-grade, self-balancing exoskeleton has been a staple in over 150 rehabilitation and research centers worldwide, providing invaluable insights and proving the efficacy of Wandercraft’s proprietary self-balancing algorithms. Atalante X has enabled countless individuals to regain or experience walking within supervised settings, laying the groundwork for a more personal and accessible solution.
The development of Eve represents a strategic evolution of this core technology. Recognizing the profound desire among wheelchair users to extend their upright mobility beyond the clinic, Wandercraft embarked on creating a device that was more compact, user-friendly, and adaptable for home and community use. The transition from a robust rehabilitation tool to a personal mobility aid required meticulous engineering, rigorous safety testing, and a deep understanding of the diverse challenges faced by individuals in their daily routines.
The chronological path to FDA clearance involved years of research, development, and comprehensive clinical trials. These trials were crucial in demonstrating Eve’s safety, functional benefits, and the ability of users and their companions to operate the device effectively in environments mimicking real-life scenarios. The iterative process of design, testing, and refinement ensured that Eve would meet the stringent requirements of a personal medical device, capable of delivering reliable and transformative assistance.
Transforming Everyday Life: Supporting Data and User Experiences
The impact of Eve extends far beyond mere physical movement; it touches upon the very fabric of daily life, fostering independence, dignity, and social inclusion. For many wheelchair users, opportunities to stand and move upright have been severely limited, often impacting simple yet profoundly meaningful interactions.
Caroline Laubach, a Wandercraft Test Pilot, eloquently articulates this transformation: "For years, I experienced much of the world while seated. Using Eve transformed ordinary moments in ways I never expected, like having conversations eye-to-eye whether seated or standing, getting a cup from the highest kitchen cabinet, and simply bringing a new type of confidence into my life." Her testimony highlights the often-overlooked psychological and social benefits of verticality, from improved self-esteem to enhanced social engagement. Imagine the simple act of looking a loved one in the eye, or retrieving an item from a shelf without assistance – these are the "extraordinary meanings" Eve promises to unlock.
Beyond anecdotal evidence, clinical data supports the multifaceted benefits of upright mobility. The Christopher & Dana Reeve Foundation reports that over five million people in the United States live with paralysis, including hundreds of thousands with spinal cord injuries. For this population, standing and moving upright are deeply meaningful experiences that affect physical health, social interactions, and participation in daily life.
The ability to perform activities of daily living (ADLs) hands-free is a cornerstone of Eve’s design. This includes tasks such as preparing meals at a kitchen counter, reaching for items in cabinets, engaging in hobbies that require standing, interacting with children or pets at their level, and participating in social gatherings with greater ease and confidence. The self-balancing technology is paramount here, as it frees the user’s hands to manipulate objects, open doors, or gesture during conversations, tasks that are often cumbersome or impossible with other mobility aids.
Rigorous Validation: The Path to FDA Clearance
FDA clearance is a rigorous process, demanding substantial evidence of a device’s safety and efficacy. For Eve, this involved a comprehensive three-site clinical trial, a testament to Wandercraft’s commitment to scientific validation. The trials were led by esteemed institutions: the James J. Peters Department of Veterans Affairs Medical Center in the Bronx, NY; Kessler Foundation in West Orange, NJ; and Walk in New York in New York City, NY.
Participants in the clinical trial represented a range of injury severities, ensuring that Eve’s capabilities were tested across a diverse user group. The focus was multifaceted, encompassing safety, functional performance, the effectiveness of training protocols, and ultimately, readiness for personal use outside of a controlled clinical environment. Participants completed structured training before undergoing a series of functional, usability, and task-based assessments specifically designed to reflect intended use in everyday settings.
The clinical program yielded compelling results, demonstrating that both participants and their specially trained companions could effectively learn to operate Eve and successfully complete activities relevant to personal use. Crucially, participants met key functional and usability endpoints, including significant improvements in measures of walking performance and the ability to execute various activities of daily living.
Dr. Gail Forrest, PhD, director of the Tim and Caroline Reynolds Center for Spinal Stimulation at Kessler Foundation, underscored the significance of these findings: "What makes these findings meaningful is that the technology was evaluated not only on engineering performance but also on how users and companions could safely integrate it into real-world activities. The combination of functional performance, usability, and user-reported outcomes gives this technology substantial clinical relevance." This holistic evaluation approach is critical for a device intended for personal, unsupervised use, highlighting its practical applicability and user-centered design.
Beyond functional improvements, participants also reported a range of broader health benefits. These included improvements in overall health status, psychological well-being, endurance during daily activities, and a reduction in lower-limb spasticity. Furthermore, some users noted positive changes in sitting balance, sleep quality, and even bladder and bowel function – aspects of health profoundly impacted by mobility limitations. These systemic benefits underscore the profound impact that restored upright mobility can have on an individual’s overall quality of life.
Pioneering Access and Commercialization: Official Responses and Implications
Wandercraft’s vision extends beyond technological innovation to ensuring broad access for qualified users. The company has made significant investments in establishing a robust infrastructure to support this commitment.
A crucial element in this endeavor is the reimbursement landscape. Medicare has provided a reimbursement pathway for eligible personal exoskeleton users since 2024, under its Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) program, utilizing billing code K1007. Wandercraft anticipates that Eve could become eligible for Medicare reimbursement within 60 to 90 days of its commercial launch. Furthermore, the company plans to broaden patient access via private payers and other funding sources, striving to make walking at home a reality for as many qualified users as possible.
To navigate the complexities of healthcare funding, Wandercraft has established a dedicated group of access specialists. These experts will work closely with users and their care teams to assist with claim submissions, clarify coverage requirements, address reimbursement questions, and explore available financing options, thereby removing significant barriers to adoption.
The commercial launch of Eve in the United States is slated for September 17, 2026. This momentous occasion will be marked by an exclusive unveiling event at the Cure healthcare innovation campus in New York City. Presented in collaboration with the United Spinal Association, as the organization celebrates its 80th anniversary, the livestreamed program will bring together individuals living with spinal cord injuries, caregivers, clinicians, researchers, policymakers, and Eve pilots. This event is designed to celebrate the transition of self-balancing exoskeleton technology from rehabilitation to personal use, symbolizing a new chapter in assistive technology. Viewers interested in witnessing this historic event can register to watch the livestream on September 17 at 6 p.m. ET via the provided link.
Before individuals can take Eve home, a structured process ensures safe and effective integration into their lives. Eve will be prescribed by licensed healthcare practitioners. Prerequisites for use include a thorough clinical assessment, an individualized device fitting, and comprehensive training with a companion. This training involves five two-hour sessions, which can be completed in as little as one week, covering essential skills such as transfers, remote-controller operation, walking on level surfaces, navigating tight spaces, performing activities of daily living, and critical safety and emergency procedures. This meticulous preparation underscores Wandercraft’s commitment to user safety and confidence.
Building the Ecosystem: Strategic Partnerships for Success
To ensure a seamless pathway from initial evaluation to white-glove delivery, Wandercraft has forged strategic partnerships with a growing network of rehabilitation centers, complex rehabilitation technology (CRT) providers, and federal distribution partners, complementing its existing walk centers worldwide.
Walk US, including its flagship Walk in New York location, specializes in neurorehabilitation using Atalante X. It will serve as a key partner for Eve evaluations, training, demonstrations, community education, and preparation for personal use at home. A second location, Walk in Miami by Wandercraft, is expected to open later this year, further expanding access.
National Seating & Mobility (NSM), North America’s largest provider of complex rehabilitation technology, has been named Wandercraft’s exclusive CRT distribution partner for Eve. Leveraging its extensive network of over 180 locations across the United States and Canada, NSM will be instrumental in supporting evaluation, access, delivery, and ongoing service for Eve users. This partnership is crucial for widespread availability and consistent support.
Good Shepherd Rehabilitation will serve as the exclusive Eve partner in Pennsylvania’s Lehigh Valley. Eligible users and their companions will have the opportunity to learn about and experience the technology at Good Shepherd’s Hyland Center, with additional access locations anticipated in the future.
Furthermore, USVetServ, a Service-Disabled Veteran-Owned Small Business, will act as an authorized independent distributor of both Eve and Atalante X for the U.S. Department of Veterans Affairs (VA), its VA Medical Centers, and other VA facilities nationwide. This partnership reflects Wandercraft’s steadfast commitment to helping veterans access the most advanced assistive technologies, acknowledging their unique needs and sacrifices.
Collectively, these organizations are building the essential clinical, reimbursement, distribution, training, and service infrastructure required to translate FDA clearance into meaningful, real-world access for eligible users across the nation.
The Broader Horizon: Impact and Future Implications
The FDA clearance of Eve marks a significant evolution in healthcare and robotics, pushing the boundaries of what is possible in assistive technology. By bringing self-balancing exoskeleton technology beyond controlled rehabilitation settings and into personal use, Wandercraft is addressing a profound unmet need for millions of individuals living with paralysis.
The implications for quality of life are immense. Increased independence in daily tasks, improved physical health outcomes, enhanced psychological well-being, and greater participation in social and community life are direct benefits. Eve represents not just a device, but a tool for reclaiming aspects of life that were previously out of reach, fostering a greater sense of autonomy and self-worth.
Looking ahead, the success of Eve could catalyze further innovation in the field of personal robotics and assistive devices. It sets a precedent for the safe and effective integration of complex technology into home environments, potentially paving the way for future advancements that offer even greater capabilities and broader applicability. Wandercraft’s commitment to continuous development, combined with its robust partnership network, positions Eve as a foundational element in the ongoing quest to enhance human mobility and empower individuals to live life to its fullest potential.
The journey from a pioneering concept to a commercially available, FDA-cleared personal exoskeleton is a testament to Wandercraft’s dedication and the collaborative efforts of clinicians, researchers, and, most importantly, the test pilots and users who have shared their experiences and shaped this transformative technology. As September 17, 2026, approaches, the world watches with anticipation as Eve prepares to step into homes, patios, and lives, promising a new horizon of upright mobility and independence.
Learn more at: Wandercraft.eu.
